Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study

Compared to PD-1 inhibitor plus chemotherapy, cadonilimab plus chemotherapy significantly improved PFS and OS with a manageable safety profile in the first-line treatment of advanced G/GEJ cancer with PD-L1 CPS <5 in a real-world setting.

Authors

Institutions

Publication Details

Journal
Journal of Gastrointestinal Oncology
Published
2026-02-01
DOI
https://doi.org/10.21037/jgo-2025-aw-866
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study

N. Zhang, Xing Yuan, Yihui Huang, Duqin Zhao et al.
Journal of Gastrointestinal Oncology
Cancer Immunotherapy and Biomarkers
article

Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study

N. Zhang, Xing Yuan, Yihui Huang, Duqin Zhao, J. Ying, Zhongyue Wu, Qing Wei, Lei Zhang, Jingjing Li, Qi Xu
article en

Abstract

Compared to PD-1 inhibitor plus chemotherapy, cadonilimab plus chemotherapy significantly improved PFS and OS with a manageable safety profile in the first-line treatment of advanced G/GEJ cancer with PD-L1 CPS <5 in a real-world setting.

Journal of Gastrointestinal OncologyVol. 17(1)
Wenzhou Medical University (CN), Zhejiang Cancer Hospital (CN), Zhejiang Medical and Health Group Hangzhou Hospital (CN), First Hospital of Jiaxing (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Hangzhou Cancer Hospital (CN)
Good health and well-being
Openalex Percentile: Top 56%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.